Triple treatment for cervical Ca shows great promise

Article

Adding hyperthermia to standard chemoradiotherapy for advanced cervical carcinoma seems to boost the positive effects of treatment without adding any negative effects, according to analysis of three phase 2 studies.

Adding hyperthermia to standard chemoradiotherapy for advanced cervical carcinoma seems to boost the positive effects of treatment without adding any negative effects, according to analysis of three phase 2 studies.

Most of 68 women with a median age of 45 years and stage IIB, III, or IVA disease received a biologically effective radiotherapy and brachytherapy dose of 86.7 gray or higher, at least four courses of 40 mg/m2 weekly cisplatin, and four weekly sessions of locoregional hyperthermia.

Ninety percent of the women achieved complete remission. After a median of 18 months, 84% of the women remained alive, 74% of whom were without recurrence. Toxicity was comparable to that with chemoradiotherapy alone. A phase 3 study of the triple treatment is underway.

Related Videos
One year out: Fezolinetant displays patient satisfaction for managing hot flashes | Image Credit: sutterhealth.org
Addressing maternal health inequities: Insights from CDC's Wanda Barfield | Image Credit: cdc.gov
Addressing racial and ethnic disparities in brachial plexus birth Injury | Image Credit: shrinerschildrens.org
Innovations in prenatal care: Insights from ACOG 2024 | Image Credit:  uofmhealth.org.
Unlocking therapeutic strategies for menopausal cognitive decline | Image Credit: uclahealth.org.
Navigating menopause care: Expert insights from ACOG 2024 | Image Credit: mayo.edu.
raanan meyer, md
Related Content
© 2024 MJH Life Sciences

All rights reserved.